X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/rigel-announces-publication-of-data-on-rezlidhia-olutasidenib-in-post-venetoclax-patients-with-mutant-idh1-aml-in-leukemia--lymphoma-302107833.html
https://www.prnewswire.com/news-releases/rigel-announces-collaboration-with-connect-to-conduct-a-phase-2-trial-of-olutasidenib-in-glioma-302026029.html
https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-and-md-anderson-announce-strategic-alliance-to-advance-rezlidhia-olutasidenib-in-aml-and-other-cancers-302009825.html
https://www.prnewswire.com/news-releases/rigel-announces-presentation-of-data-from-analysis-of-rezlidhia-olutasidenib-in-post-venetoclax-patients-with-mutant-idh1-aml-301844657.html
https://www.prnewswire.com/news-releases/rigel-announces-publication-of-rezlidhia-olutasidenib-phase-2-clinical-results-in-blood-advances-301737877.html
https://www.prnewswire.com/news-releases/national-comprehensive-cancer-network-adds-newly-approved-rezlidhia-olutasidenib-to-clinical-practice-guidelines-in-oncology-for-acute-myeloid-leukemia-301724233.html
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.biopharmadive.com/news/rigel-pharmaceuticals-leukemia-rezlidhia-fda-approval/637843/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-rigel-pharmas-leukemia-treatment-2022-12-01/
https://www.europeanpharmaceuticalreview.com/news/177058/fda-approves-rezlidhia-for-acute-myeloid-leukaemia/
https://www.pharmaceutical-technology.com/news/rigel-forma-licence-deal/
https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-and-forma-therapeutics-announce-licensing-agreement-for-olutasidenib-a-novel-mutant-idh1-inhibitor-for-the-potential-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-301598297.html
https://endpts.com/forma-takes-aim-at-agios-with-new-aml-complete-remission-data/?utm_medium=email&utm_campaign=1089%20-%20GSK%20pays%20angry%20discovery%20partner%20to%20protect%20its%20oncology%20strategy%20Stelios%20Papadopoulos%20jumps%20into%20the%20SPAC%20game%20Basic&utm_content=1089%20-%20GSK%20pays%20angry%20discovery%20partner%20to%20protect%20its%20oncology%20strategy%20Stelios%20Papadopoulos%20jumps%20into%20the%20SPAC%20game%20Basic+CID_842d26f8e652b473f76b5d6c176e8621&utm_source=ENDPOINTS%20emails&utm_term=Forma%20takes%20aim%20at%20Agios%20with%20new%20AML%20complete%20remission%20data
https://www.businesswire.com/news/home/20200528005414/en/Forma-Therapeutics-Announces-Clinical-Data-Presented-ASCO20
https://www.businesswire.com/news/home/20191209005557/en/FORMA-Therapeutics-Announces-Positive-Preliminary-Phase-12/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
Market Place
Share 
